The safety, immunogenicity, and efficacy of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: a randomized, open-label, active-controlled phase 3 trial.

Details

Language :

English

ISSN :

22221751

Volume :

13

Issue :

1

Database :

Complementary Index

Journal :

Emerging Microbes & Infections

Publication Type :

Academic Journal

Accession number :

177810624

Full Text :

https://doi.org/10.1080/22221751.2024.2320913